A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

RECRUITING

Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 275293, Kaohsiung City

RECRUITING

Austin Health /ID# 275505, Heidelberg

RECRUITING

The Queen Elizabeth Hospital /ID# 275719, Woodville

RECRUITING

St John Of God Murdoch Hospital /ID# 275700, Murdoch

RECRUITING

Chungbuk National University Hospital /ID# 275768, Cheongju-si

RECRUITING

Mid Florida Hematology And Oncology Center /ID# 275278, Orange City

RECRUITING

Inje University Haeundae Paik Hospital /ID# 275388, Busan

RECRUITING

The Iowa Clinic /ID# 276020, West Des Moines

RECRUITING

Nho - Revive Research Institute /ID# 276115, Lincoln

RECRUITING

Renown Regional Medical Center /ID# 276049, Reno

RECRUITING

USC Norris Comprehensive Cancer Center /ID# 275343, Los Angeles

RECRUITING

Rambam Health Care Campus /ID# 274542, Haifa

RECRUITING

Rabin Medical Center /ID# 274540, Petah Tikva

RECRUITING

The Chaim Sheba Medical Center /ID# 274541, Ramat Gan

RECRUITING

Osaka Medical And Pharmaceutical University Hospital /ID# 275684, Takatsuki

RECRUITING

Unidade Local de Saude de Braga, EPE /ID# 275394, Braga

RECRUITING

Unidade Local de Saude de Santo Antonio, E.P.E. /ID# 275387, Porto

RECRUITING

Hospital Cuf Porto /ID# 275395, Porto